Sankyo

Sam Chun Dang Pharm announced a joint development and commercialization agreement with Daiichi Sankyo for its oral weight-loss pill, triggering a more than 75% share rally this month and lifting chairman Yoon Dae-in into billionaire status. The company’s S-Pass technology converts injectables into pills and has attracted bullish analyst coverage; SCD is also pursuing a potentially $2 billion deal with Takeda for a long-acting injectable using its microsphere platform. SCD reported revenue growth and a 76% rise in net income year‑over‑year for the first nine months of 2025, supporting investor optimism. » More on forbes.com

Daiichi Sankyo and AstraZeneca have treated the first patient in the global phase‑3 DESTINY‑Lung06 study of ENHERTU in combination with Pembrolizumab as first‑line therapy for inoperable, locally advanced or metastatic HER2‑overexpressing NSCLC. The randomized trial is expected to enroll about 686 patients; the primary endpoint is progression‑free survival, with overall survival as an important secondary endpoint. The aim is to determine whether ENHERTU can replace platinum‑based chemotherapy in standard first‑line therapy and improve outcomes, as no HER2‑targeted first‑line drugs are currently approved for this patient group. » More on de.investing.com

The FDA has designated Raludotatug Deruxtecan from Daiichi Sankyo and Merck as a Breakthrough Therapy for the treatment of adult patients with platinum-resistant, CDH6-expressing ovarian, primary peritoneal, or fallopian tube cancer. The decision is based on data from a Phase 1 study and the ongoing Phase 2/3 study REJOICE-Ovarian01, whose Phase 3 portion has objective response rate and progression-free survival as primary endpoints. This is the first BTD for Raludotatug Deruxtecan and the second BTD since the collaboration between the two companies began. » More on de.investing.com